Ersi Voskaridou
Athens, ESYE31, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Journal: The Lancet. Haematology
Published: September 24, 2024
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Journal: European journal of haematology
Published: December 21, 2022
The Optimized γ-Globin Lentiviral Vector GGHI-mB-3D Leads to Nearly Therapeutic HbF Levels In Vitro in CD34+ Cells from Sickle Cell Disease Patients.
Journal: Viruses
Published: September 20, 2022
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Journal: The Lancet. Haematology
Published: May 06, 2022
Droplet Digital PCR for Non-Invasive Prenatal Detection of Fetal Single-Gene Point Mutations in Maternal Plasma.
Journal: International journal of molecular sciences
Published: January 27, 2022
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Journal: Therapeutic advances in hematology
Published: January 10, 2022
Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
Journal: American journal of hematology
Published: July 01, 2021
Last Updated: 09/26/2026